Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Ensysce Biosciences, Inc. (ENSC) had Normalized Pre-Tax Income of $-3.56M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$0.96M |
|
$-3.56M |
|
-- |
|
$0.96M |
|
$4.52M |
|
$-3.56M |
|
$0.01M |
|
$-3.56M |
|
|
Normalized Pre-Tax Income |
$-3.56M |
$-3.56M |
|
$-3.56M |
|
$-3.56M |
|
$-3.56M |
|
$-3.56M |
|
$-3.56M |
|
6.84M |
|
6.84M |
|
$-0.52 |
|
$-0.52 |
|
| Balance Sheet Financials | |
$2.01M |
|
$0.12M |
|
$0.16M |
|
$2.17M |
|
$2.84M |
|
-- |
|
-- |
|
$2.84M |
|
$-0.67M |
|
$-0.67M |
|
$-0.67M |
|
9.28M |
|
| Cash Flow Statement Financials | |
$-3.50M |
|
-- |
|
$-0.06M |
|
$4.31M |
|
$0.75M |
|
$-3.56M |
|
$0.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.71 |
|
-- |
|
-- |
|
-- |
|
-0.37 |
|
100.00% |
|
-370.68% |
|
-370.68% |
|
-- |
|
-370.07% |
|
-370.07% |
|
$-3.50M |
|
-- |
|
-- |
|
-- |
|
0.44 |
|
-- |
|
-- |
|
-- |
|
531.59% |
|
531.59% |
|
-164.06% |
|
531.59% |
|
$-0.07 |
|
$-0.51 |
|
$-0.51 |
|